Precigen director Jeffrey Kindler sells $1.38m in stock By Investing.com

Jeffrey B. Kindler, a director at Precigen, Inc. (), sold 185,000 shares of the company’s common stock on August 26, 2026. The series of transactions amounted to a total value of $1,376,400.

The shares were sold at prices ranging from $7.38 to $7.59 per share, with a weighted average price of $7.44. Following these sales, Kindler directly holds 17,100 shares of Precigen common stock.The insider sale comes as Precigen stock trades at $6.95, near its 52-week high of $7.71, following a remarkable 83% surge over the past six months. According to InvestingPro analysis, the stock appears undervalued at current levels, with a Fair Value of $7.46. Investors seeking deeper insights can access comprehensive analysis and 11 additional ProTips on the platform’s detailed Pro Research Report.

In other recent news, Precigen reported a significant second-quarter performance, surpassing forecasts with strong earnings and revenue results. The company achieved earnings of $0.05 per share, significantly outperforming analyst expectations of a $0.01 loss. Revenue reached $54.98 million, nearly doubling the anticipated $27.83 million. This impressive financial outcome was largely attributed to robust demand for PAPZIMEOS, Precigen’s therapy for adult recurrent respiratory papillomatosis. Analysts had not anticipated such a strong performance, highlighting the unexpected success of the therapy. Additionally, Precigen reported a net income of $20.1 million for the quarter. These developments indicate a notable turnaround for the company, as it swung to profitability. The positive earnings report has garnered attention from investors and analysts alike.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.